Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
33%
Ph phase_1
5
56%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(1)
Other(8)

Detailed Status

unknown8
Completed1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (62.5%)
Phase 23 (37.5%)

Trials by Status

unknown889%
completed111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

NCT04279405
unknownphase_2

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

NCT05274997
unknown

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer

NCT04975061
unknownphase_1

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT04108325
unknownphase_1

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

NCT04500561
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04279405Phase 1

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Completed
NCT05274997Phase 2

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Unknown
NCT04975061

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer

Unknown
NCT04108325Phase 1

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Unknown
NCT04500561Phase 1

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Unknown
NCT04370405Phase 2

A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Unknown
NCT04379167Phase 2

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

Unknown
NCT04049929Phase 1

A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Unknown
NCT03757000Phase 1

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9